Stifel Nicolaus Issues Positive Forecast for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price

Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by investment analysts at Stifel Nicolaus from $200.00 to $207.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Stifel Nicolaus’ price target would suggest a potential upside of 66.56% from the stock’s previous close.

Several other research analysts have also issued reports on the stock. Jefferies Financial Group increased their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research report on Tuesday, August 13th. Wells Fargo & Company lifted their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Wedbush reissued an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a research report on Friday. The Goldman Sachs Group lifted their target price on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Finally, Bank of America upped their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, Ascendis Pharma A/S has an average rating of “Moderate Buy” and a consensus target price of $193.08.

Ascendis Pharma A/S Price Performance

Shares of ASND opened at $124.28 on Friday. The business’s fifty day moving average price is $132.15 and its 200 day moving average price is $132.80. The stock has a market capitalization of $7.54 billion, a PE ratio of -13.35 and a beta of 0.66. Ascendis Pharma A/S has a 12-month low of $90.13 and a 12-month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. As a group, research analysts anticipate that Ascendis Pharma A/S will post -7.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several large investors have recently bought and sold shares of the business. Signaturefd LLC boosted its position in Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares during the period. Bessemer Group Inc. raised its stake in shares of Ascendis Pharma A/S by 61.0% in the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 332 shares during the last quarter. Searle & CO. acquired a new stake in Ascendis Pharma A/S during the 2nd quarter worth about $205,000. Rhumbline Advisers raised its position in Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 143 shares in the last quarter. Finally, Pursue Wealth Partners LLC acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at $217,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.